Clinicoradiological Profile of Lung Cancer

Authors

  • Deepak Nagar Associate Professor & HOD, Department of TB & Chest, GMC Ratlam, Madhya Pradesh, India
  • Kamal Nayan Shringi Assistant Professor, Department of TB & Chest, GMC Ratlam,Madhya Pradesh, India
  • Bharat Kumawat Senior Resident, Department of TB & Chest, GMC Ratlam, Madhya Pradesh, India

Keywords:

Squamous cell carcinoma ,adenocarcinoma ,Cisplatin , Irinotecan

Abstract

Objective:To study clinico-radiological profile of patients of lung cancer and to determine the response to Cisplatin and Irinotecan as chemotherapeutic regimen in appropriately staged IIIB/ IV cases of non small cell lung CancerMethods: All consecutive patients of lung cancer more than 18 years of age were evaluated and staged using standard protocol .All patients with stage III-B and IV non small cell lung cancer were assessed. 20 patients with ECOG score 0, 1 or 2 in the study were enrolled and subjected to chemotherapy regimen .Controls were provided basic supportive care (BSC) including antibiotics, analgesics, bronchodilators and supportive measures.Results:Of 137 patients enrolled the mean age of patients was 57.16 .109 patients (79.6%) were males with Sex Ratio of 3.9:1.The commonest symptom was cough in 109 patients The mean duration of symptom was 5.52 months + SD 6.23. Smoking was found to be present in (85.4%) Majority of the patients were bidi smokers .The commonest sign observed was that of a mass lesion in 78 patients (56.93%) followed by that of collapse .On chest X ray, mass lesion was the most common finding (64.96%) followed by pleural effusion in 40 (29.19) .The commonest paraneoplastic syndrome observed was anorexia in 79 patients (57.66%), cachexia in 63 .Squamous cell carcinoma lung was the commonest histological subtype among male patients (42 out of 96— 43.8%), while adenocarcinoma was the commonest histological subtype among the female patients (10 out of 25-40%)Conclusion:Cisplatin and Irinotecan regimen showed improvement in the median survival and 1 year survival rates (57 weeks and 53% respectively) as compared to basic supportive care. The regimen is cheap; its side effects are mild,tolerable reasonable regimen in resource limited settings.

Downloads

Published

2021-08-30

How to Cite

Deepak Nagar, Kamal Nayan Shringi, & Bharat Kumawat. (2021). Clinicoradiological Profile of Lung Cancer. International Journal of Health and Clinical Research, 4(15), 408–413. Retrieved from https://ijhcr.com/index.php/ijhcr/article/view/3051